Efficacy and safety of sorafenib for advanced renal cell carcinoma: real-world data of patients with renal impairment

// Katsunori Tatsugami 1 , Mototsugu Oya 2 , Koki Kabu 3 and Hideyuki Akaza 4 1 Department of Urology, Graduate School of Medical Science, Kyushu University, Higashi-ku, Fukuoka City 812-8582, Japan 2 Department of Urology, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan 3 Medical Affairs Oncology and Hematology, Bayer Yakuhin, Ltd., Chiyoda-ku, Tokyo 100-8265, Japan 4 Department of Strategic Investigation on Comprehensive Cancer Network, Interfaculty Initiative in Information Studies/Graduate School of Interdisciplinary Information Studies, The University of Tokyo, Meguro-ku, Tokyo 153-8904, Japan Correspondence to: Katsunori Tatsugami, email: ktatsu@uro.med.kyushu-u.ac.jp Keywords: sorafenib; advanced RCC; eGFR; real-world data; propensity score matching Received: January 12, 2018 Accepted: February 23, 2018 Published: April 10, 2018 ABSTRACT Background: We retrospectively analysed the efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with renal impairment. Methods: Patients were divided into two groups by an estimated glomerular filtration rate (eGFR) cut-off of 45 mL/min/1.73 m 2 . Background factors considered to affect prognosis were well balanced by propensity score matching between the groups. Demographics, dose modification, adverse events, tumour response, progression-free survival, and renal function (eGFR) were evaluated. Results: Among 935 and 2008 patients with an eGFR of